Molecular disease monitoring using circulating tumor DNA in myelodysplastic syndromes

Paul Yeh; Michael Dickinson; Sarah Ftouni; Tane Hunter; Devbarna Sinha; Stephen Q Wong; Rishu Agarwal; Ravikiran Vedururu; Kenneth Doig; Chun Yew Fong; Piers Blombery; David Westerman; Mark A Dawson; Sarah-Jane Dawson

Journal article

Molecular disease monitoring using circulating tumor DNA in myelodysplastic syndromes

Paul Yeh, Michael Dickinson, Sarah Ftouni, Tane Hunter, Devbarna Sinha, Stephen Q Wong, Rishu Agarwal, Ravikiran Vedururu, Kenneth Doig, Chun Yew Fong, Piers Blombery, David Westerman, Mark A Dawson, Sarah-Jane Dawson

Blood | AMER SOC HEMATOLOGY | Published : 2017

DOI: 10.1182/blood-2016-09-740308

University of Melbourne Researchers

Mark Dawson Author The Sir Peter MacCallum Department of Oncology

David Westerman Author Medicine - St Vincent's Hospital

Michael Dickinson Author The Sir Peter MacCallum Department of Oncology

Sarah-Jane Dawson Author The Sir Peter MacCallum Department of Oncology

Related Projects (5)

Epigenetic Regulation Of Self Renewal And Lineage Commitment In Haematopoiesis

The process by which all our mature blood cells are produced and sustained remains largely unknown. Underpinning the cell fate decisions mad..

Circulating Tumour Dna As A Noninvasive Biomarker In Melanoma

The expanding repertoire of treatment options in melanoma is bringing into focus the need for improved ways to accurately monitor treatment ..

Clonal Evolution In Myelodysplasia And Acute Myeloid Leukaemia Following Azacitidine

The myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) represent a spectrum of clinically heterogeneous malignancies that rema..

Circulating Tumour Dna To Monitor Treatment Response And Resistance In Chronic Lymphocytic Leukaemia

Many cancers shed small amounts of DNA (ctDNA) into the patient’s bloodstream and recent advances in genomic technologies now allow levels o..

Epigenetic Therapies As Molecular Probes To Investigate The Molecular Pathogenesis Of Leukaemia

A major limitation to the success of targeted therapies in cancer is the fact that we have few if any tools to study in detail their mechani..

Grants

Awarded by National Health and Medical Research Council of Australia

Funding Acknowledgements

This work was funded by a Senior Leukaemia Foundation Australia Fellowship and VESKI Innovation Fellowship (M.A.D.), a National Breast Cancer Foundation and Victorian Cancer Agency Fellowship (S.-J.D.). National Health and Medical Research Council of Australia grants 1128984, 1106444, and 1106447 ( M.A.D.) and 1107126 and 1104549 (S.-J.D.) partly funded this research. This work was also supported by the Klempfner Epigenetics Fellowship administered by the Snowdome Foundation and the Haematology Society of Australia and New Zealand young investigator grant (P.Y.).The clinical study patient recruitment was funded by the Victorian Cancer Agency, Celgene, and GlaxoSmithKline.